A 24-week phase IIb, randomized, double-blind, placebo-controlled, multicenter study to investigate the efficacy and safety of tregalizumab (BT061) in combination with methotrexate in the treatment of subjects with active rheumatoid arthritis who have had an inadequate response to methotrexate alone, followed by a 24-week extension phase:T cell REgulating Arthritis Trial 2b (TREAT 2b)
Phase of Trial: Phase II
Latest Information Update: 28 Jan 2016
At a glance
- Drugs Tregalizumab (Primary) ; Methotrexate
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms TREAT-2b
- Sponsors Biotest AG
- 11 Jan 2016 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record.
- 11 Aug 2015 According to a Biotest AG media release, following a detailed analysis of the data from this phase IIb "Treat 2bStudy" of tregalizumab (BT-061) for rheumatoid arthritis, BT-061 showed a dose-dependent effect on cells in the immune system which did not translate into clinical efficacy. As a result, Biotest will discontinue the clinical development of tregalizumab (BT-061).
- 24 Jun 2015 According to a Biotest media release, data from this study will be presented at the conference of the American College of Rheumatologyin.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History